Search

You searched for "management"

640 results found

Metabolic stone disease for urology trainees

3 July 2026 | | URO - Endourology & Stones
Urolithiasis continues to be a heavy burden on the worldwide medical infrastructure with an estimated 106 million cases recorded internationally in 2021 [1]. Whilst incidence rates have started to decline across Europe and high-income North America, there are emerging hotspots...

‘One team’: our experience teaching catheter care and difficult urethral catheterisation to NHS Nightingale Hospital London volunteer staff members

4 September 2020 | | URO - Functional / Reconstructive Urology, URO - Technology
The NHS Nightingale Hospital London was launched in response to the COVID-19 pandemic. In mid-March 2020, the predicted scale of the pandemic was uncertain and there was concern that COVID-19 might overwhelm existing intensive care unit (ICU) capacity within weeks....

Sarcomatoid renal cell carcinoma

1 September 2017 | | URO - Urologic Oncology
Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...

Bladder cancer: where are we with intravesical therapies?

1 July 2016 | | URO - Urologic Oncology
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...

What is the role of evidence-based medicine in urology?

1 March 2016 | | URO - Basic Science Research
The concept of ‘evidence-based medicine’ (EBM) was first developed in the early 1990s and was described as “the conscientious, explicit and judicious use of the current best evidence in making decisions about the care of individual patients” by the recently...

Józef Dietl – more than one crisis

5 September 2022 | | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). To urologists, the name Dietl is linked with the eponym of Dietl’s crisis,...

Non-urothelial bladder malignancies

3 May 2024 | | URO - Urologic Oncology
Case 1 An 80-year-old gentleman presented with a history of visible haematuria and recurrent urinary tract infections (UTIs). He has been performing intermittent self catheterisation (ISC) for detrusor underactivity for over 20 years. A flexible cystoscopy showed these appearances of...

The role of embolisation in urology

3 September 2024 | | URO - Functional / Reconstructive Urology, URO - Urologic Oncology
Case 1 An 86–year–old male presented with visible haematuria and suprapubic pain. He had a history of diabetes, heart failure, benign prostatic hypertrophy, aortic valve replacement, deep vein thrombosis (DVT) and atrial fibrillation (AF) and was anticoagulated on a non-VKA...

So you want to go on a Fellowship: part 1

1 January 2016 | | URO - Core Urology
Look out for part 2 of this series later in 2016 when the author will discuss settling into the research role of his fellowship and will reflect on his first year overseas. This is the first in a series of...

An overview of non-surgical treatment options for Peyronie’s disease

3 May 2022 |
Peyronie’s disease (PD) is a therapeutic challenge despite the availability of several non-surgical and surgical options. Very few of these options are supported by good quality evidence according to the current American and European guidelines [1-3]. The period of plaque...

Localised renal cancer

4 September 2025 | | URO - Urologic Oncology, URO - Uroradiology
Case 1 A 56-year-old lady is referred to the urology clinic after the GP conducted an ultrasound abdomen for deranged liver function tests and found a renal lesion. She is otherwise fit and well. Figure 1. What is the sensitivity...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...